Trial Profile

A Phase Ib Study of Multivalent Autophagosome Vaccine, With or Without GITR Agonist, With Sequenced Checkpoint Inhibition (Anti-PD-1) - Immunotherapy Trio in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DPV 001 (Primary) ; Ragifilimab (Primary) ; Retifanlimab (Primary) ; Cyclophosphamide
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms GITRVax

07 Nov 2024 According to an UbiVac Media Release, updated results from a Phase 1b study presented at this year's Society for Immunotherapy of Cancer (SITC) Annual Meeting.
07 Nov 2024 Results presented in an UbiVac Media Release
18 Jun 2024 Planned End Date changed from 31 Jul 2024 to 31 Dec 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com